In pursuit of better treatment options for malignant tumors, metal-based complexes continue to show promise as attractive chemotherapeutics due to tunability, novel mechanisms, and potency exemplified by platinum agents. The metabolic character of tumors renders the mitochondria and other metabolism pathways fruitful targets for medicinal inorganic chemistry. Cumulative understanding of the role of mitochondria in tumorigenesis has ignited research in mitochondrial targeting metal-based complexes to overcome resistance and inhibit tumor growth with high potency and selectivity. Here, we discuss recent progress made in third row transition metal-based mitochondrial targeting agents with the goal of stimulating an active field of research toward new clinical anticancer agents and the elucidation of novel mechanisms of action.
|Journal||Current Opinion in Chemical Biology|
|State||Published - Feb 2023|
Bibliographical noteFunding Information:
This work was supported by grant R01CA258421-01 from the National Cancer Institute .
© 2022 Elsevier Ltd
- Metal-based drugs
ASJC Scopus subject areas
- Analytical Chemistry